Gal-3 blocks the binding between PD-1 and pembrolizumab.

ABSTRACT:

Introduction

Immune checkpoint inhibitors (ICI) have revolutionized the treatment of metastatic malignant melanoma (MM) and improved long-term survival. Despite the impressive results, some patients still have progressive disease, and the search for biomarkers predicting response to ICI treatment is ongoing. In this search, galectin-3 (Gal-3) has been suggested as a molecule of interest, both as a marker of treatment response and as a treatment target to potentiate ICI therapy. We have previously demonstrated the binding between programmed cell death 1 (PD-1) and Gal-3, and here, we investigated the interaction between PD-1, pembrolizumab, and Gal-3 in metastatic MM patients.

Methods

The binding between PD-1, pembrolizumab and Gal-3 was investigated by surface plasmon resona

SUBMITTER: Greisen SR 

PROVIDER: S-EPMC11448214 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature